Document is current
Any future updates will be listed below
-
Authors
Pardo-Cea, Miguel Angel
Farré, Xavier
Esteve, Anna
Palade, Joanna
Espín, Roderic
Mateo, Francesca
Alsop, Eric
Alorda, Marc
Blay, Natalia
Baiges, Alexandra
Shabbir, Arzoo
Comellas, Francesc
Gómez, Antonio
Arnan, Montserrat
Teulé, Alex
Salinas, Monica
Berrocal, Laura
Brunet, Joan
Rofes, Paula
Lázaro, Conxi
Conesa, Miquel
Rojas, Juan Jose
Velten, Lars
Fendler, Wojciech
Smyczynska, Urszula
Chowdhury, Dipanjan
Zeng, Yong
He, Housheng Hansen
Li, Rong
Van Keuren-Jensen, Kendall
de Cid, Rafael
Pujana, Miquel Angel http://orcid.org/0000-0003-3222-4044
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI21/01306, CIBERONC, CIBERES)
Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (SGR 2017-449, 2021-184, SGR 2017-1282)
Departament de Salut, Generalitat de Catalunya (SLT017-20-000076, SLT017-20-000072, MedPerCan, URDCat)
National Cancer Institute (CA282303)
European Regional Development Fund (001-P-001647)
- License Information
-
More Information
Article History
Received: 11 August 2023
Accepted: 22 January 2024
First Online: 2 February 2024
Declarations
:
: All research was carried out in accordance with relevant national and European guidelines and regulations. The study of UKBB individual data was approved with reference 61744. The study of plasma biomarkers was approved by IDIBELL’s Ethics Committee with reference PR217/21. The GCAT study was carried out using anonymized data provided by the Catalan Agency for Quality and Health Assessment, within the framework of the PADRIS Program. The participants provided informed written consent. The research conformed to the principles of the Helsinki Declaration.
: Not applicable.
: The authors declare that they have no competing interests.
